PT771147E - Composições e métodos para imunidade celular tumoral in vivo melhorada - Google Patents

Composições e métodos para imunidade celular tumoral in vivo melhorada Download PDF

Info

Publication number
PT771147E
PT771147E PT95928099T PT95928099T PT771147E PT 771147 E PT771147 E PT 771147E PT 95928099 T PT95928099 T PT 95928099T PT 95928099 T PT95928099 T PT 95928099T PT 771147 E PT771147 E PT 771147E
Authority
PT
Portugal
Prior art keywords
subject
cancer
methods
vivo
compositions
Prior art date
Application number
PT95928099T
Other languages
English (en)
Inventor
Habib Fakhrai
Oliver Dorigo
Robert E Sobol
Original Assignee
Novarx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novarx Inc filed Critical Novarx Inc
Publication of PT771147E publication Critical patent/PT771147E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT95928099T 1994-07-18 1995-07-18 Composições e métodos para imunidade celular tumoral in vivo melhorada PT771147E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/276,694 US5772995A (en) 1994-07-18 1994-07-18 Compositions and methods for enhanced tumor cell immunity in vivo

Publications (1)

Publication Number Publication Date
PT771147E true PT771147E (pt) 2009-11-25

Family

ID=23057711

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95928099T PT771147E (pt) 1994-07-18 1995-07-18 Composições e métodos para imunidade celular tumoral in vivo melhorada

Country Status (10)

Country Link
US (4) US5772995A (pt)
EP (1) EP0771147B1 (pt)
JP (2) JP3839843B2 (pt)
AT (1) ATE442045T1 (pt)
CA (1) CA2195334C (pt)
DE (1) DE69535999D1 (pt)
DK (1) DK0771147T3 (pt)
ES (1) ES2334407T3 (pt)
PT (1) PT771147E (pt)
WO (1) WO1996002143A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
ES2263205T3 (es) * 1997-04-30 2006-12-01 Hans Klingemann Estirpes celulares citoliticas naturales y metodos de uso.
US8034332B2 (en) * 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
JP4768122B2 (ja) * 1998-02-20 2011-09-07 ユニバーシティー オブ マイアミ 改変型熱ショックタンパク質−抗原性ペプチド複合体
EP1089764B1 (en) 1998-06-10 2004-09-01 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Stimulating the immune system
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US20030190322A1 (en) * 2000-03-31 2003-10-09 Peter Kaastrup Immunostimulating properties of a fragment of tgf-beta
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
AU2001253031A1 (en) * 2000-03-31 2001-10-15 Novarx Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor
EP1292330A1 (en) * 2000-03-31 2003-03-19 Vaccine Chip Technology APS Immunostimulating properties of a fragment of tgf- beta
EP1366366B1 (en) 2000-05-10 2010-10-20 Signe BioPharma Inc. Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
CN100589845C (zh) * 2001-03-07 2010-02-17 麦康公司 用于治疗癌症的抗新血管系统制剂
AU2002303234A1 (en) * 2001-04-02 2002-10-15 Cytoprint, Inc. Methods and apparatus for discovering, identifying and comparing biological activity mechanisms
US20030125251A1 (en) * 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
US20030044393A1 (en) * 2001-07-06 2003-03-06 Annie-Chen Tran Method for increasing tumor cell immunogenicity using heat shock protein
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
BRPI0307070A2 (pt) * 2002-01-22 2019-03-26 Genzyme Corporation uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante
EP1572978A4 (en) * 2002-10-16 2006-05-24 Univ Texas COMBINATORIAL BANKS OF APTAMERS WITH OLIGONUCLEOTIDE OLIGONUCLEOTIDE PHOSPHOROTHIOATE AND PHOSPHORODITHIOATE GROUPS RELATED TO BALLS
JP4989850B2 (ja) * 2002-10-25 2012-08-01 アメリカ合衆国 ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
CA2526690C (en) * 2003-05-23 2014-01-14 Board Of Regents The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
EP1722823A2 (en) * 2004-02-27 2006-11-22 Antisense Pharma GmbH Pharmaceutical composition
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP1809324A4 (en) * 2004-10-13 2009-02-25 Univ Ohio State Res Found METHODS OF TREATING OR PREVENTING LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH VIRUSES
WO2006089251A2 (en) * 2005-02-17 2006-08-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SYNERGISTIC EFFECT OF TGF-β BLOCKADE AND IMMUNOGENIC AGENTS ON TUMORS
US20060281702A1 (en) * 2005-05-18 2006-12-14 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate aptamers for RNases
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP2918288B1 (en) * 2006-10-03 2017-08-16 Genzyme Corporation Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
EP1920782A1 (en) * 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
EP2101812A1 (en) * 2006-12-20 2009-09-23 Novarx Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization
AU2009223838B2 (en) 2008-03-03 2012-07-26 The University Of Miami Allogeneic cancer cell-based immunotherapy
CA2718884C (en) 2008-03-20 2016-11-22 University Of Miami Heat shock protein gp96 vaccination and methods of using same
SI3117709T1 (sl) 2010-03-12 2018-12-31 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
WO2012158866A2 (en) 2011-05-19 2012-11-22 The Johns Hopkins University Treatment of autoimmune disorders and infections using antagonists of sgk1 activity
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US20150037357A1 (en) * 2011-12-23 2015-02-05 Novarx Corporation Immune stimulation/metabolic inhibition as antitumor therapy
ES2917222T3 (es) 2011-12-28 2022-07-07 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
EP2917336B1 (en) * 2012-11-09 2018-06-27 Marco Archetti Diffusible factors and cancer cells
RU2712967C2 (ru) 2013-10-31 2020-02-03 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтическое средство против заболеваний, связанных с гибелью клеток эндотелия роговицы, обусловленной состоянием эндоплазматического ретикулума
EP3122884B1 (en) * 2014-03-26 2019-12-25 Tocagen Inc. A retroviral vector having immune-stimulating activity
AU2016215175B2 (en) 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
WO2019045086A1 (ja) * 2017-08-29 2019-03-07 林化成株式会社 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
JP2021521135A (ja) * 2018-04-10 2021-08-26 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ がん細胞を標的とする近赤外光線免疫療法および宿主免疫活性化の組合せ
WO2021113328A1 (en) * 2019-12-03 2021-06-10 Neuvogen, Inc. Tumor cell vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5681562A (en) * 1991-06-25 1997-10-28 Sidney Kimmel Cancer Center Lymphokine gene therapy of cancer
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
ES2144426T3 (es) * 1991-10-25 2000-06-16 Sidney Kimmel Cancer Ct Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.
WO1994025588A2 (en) * 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
EP0695354B1 (en) 1993-04-30 2002-01-09 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta1 (tgf-beta1)
EP0721351A4 (en) * 1993-09-07 1998-08-19 Sidney Kimmel Cancer Ct HAPLOTYPE MATCHED CYTOKINE SECRETARY CELLS AND METHODS OF USE IN STIMULATING AN IMMUNE RESPONSE
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells

Also Published As

Publication number Publication date
US5772995A (en) 1998-06-30
DE69535999D1 (de) 2009-10-22
US20020192199A1 (en) 2002-12-19
JP2001526622A (ja) 2001-12-18
US6120763A (en) 2000-09-19
JP3839843B2 (ja) 2006-11-01
CA2195334A1 (en) 1996-02-01
JP2006217924A (ja) 2006-08-24
ES2334407T3 (es) 2010-03-09
US8444964B2 (en) 2013-05-21
ATE442045T1 (de) 2009-09-15
US6447769B1 (en) 2002-09-10
AU3217895A (en) 1996-02-16
EP0771147A4 (en) 2004-06-16
EP0771147B1 (en) 2009-09-09
EP0771147A1 (en) 1997-05-07
WO1996002143A1 (en) 1996-02-01
AU711730B2 (en) 1999-10-21
CA2195334C (en) 2013-03-19
DK0771147T3 (da) 2010-01-04

Similar Documents

Publication Publication Date Title
EP0771147A4 (en) METHOD AND COMPOSITIONS FOR INCREASED TUMOR CELL IMMUNITY IN VIVO
AU5756298A (en) Attenuated salmonella strain used as a vehicle for oral immunization
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
AU693747B2 (en) Imidazo(4,5-c)pyridin-4-amines
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
CA2103458A1 (en) Method and composition to reduce myocardial reperfusion injury
EP0283675A3 (en) Dental plaque and dental caries inhibiting agent and compositions containing such an agent
PL330324A1 (en) Method of treating diarrhoea
AU4959997A (en) Suppression of tnf alpha and il-12 in therapy
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
EP0637246A4 (en) METHODS OF TREATING CANCER WITH C-REACTIVE PROTEIN.
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
MY106109A (en) 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions
ZA200005413B (en) Cholesterol sulfate compositions for enhancement of stratum corneum function.
IL123642A0 (en) Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration
AU8239298A (en) Nucleotide-comprising composition
IL116887A0 (en) Cationic copolymers of vinyl amine and vinyl alcohol for the delivery of oligonucleotides
AU3658793A (en) Bimodal molecular weight hyaluronate formulations and methods for using same
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
EP0303681A4 (en) IMMUNOSUPPRESSION IN THE TREATMENT OF PEOPLE BASED ON IMMUNOTOXIN.
IL131478A0 (en) Methods for treatment of scar tissue
HK1032360A1 (en) Combination therapy for the treatment of tumors.
IE872589L (en) Treated lipid regulator
IL127851A0 (en) Inhibition of TNF activity